Table 2.
Changes in LH, FSH, and estradiol levels during and after GnRHa treatment
| Variable | LH (IU/L) |
FSH (IU/L) |
Estradiol (pg/mL) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| TP 3-mo | TA 1-mo | P-value | TP 3-mo | TA 1-mo | P-value | TP 3-mo | TA 1-mo | P-value | |
| At baseline† | 17.5±12.9 | 15.2±14.5 | 0.503 | 14.4±12.0 | 16.7±6.6 | 0.312 | 0.8±4.4 | 2.1±3.1 | 0.176 |
| At 6 months‡ | 1.4±1.5 | 0.5±0.3 | 0.005 | 2.6±1.6 | 1.4±0.8 | 0.001 | 0.6±2.0 | 1.4±2.6 | 0.162 |
| At 12 months‡ | 1.0±0.7 | 0.4±0.4 | <0.001 | 3.1±1.5 | 1.5±0.7 | <0.001 | 0.4±1.4 | 0.9±2.8 | 0.333 |
| At the end of treatment‡ | 0.7±0.6 | 0.5±0.4 | 0.073 | 3.3±1.1 | 2.1±0.9 | <0.001 | 0 | 0.6±1.8 | 0.034 |
| One year posttreatment§ | 5.5±4.1∥ | 5.2±3.1 | 0.808 | 5.3±1.6º | 4.8±1.3 | 0.220 | 3.0±8.8º | 5.7±5.4 | 0.162 |
Values are presented as mean±standard deviation.
LH, luteinizing hormone; FSH, follicle-stimulating hormone; GnRHa, gonadotropin-releasing hormone agonist; TP 3-mo, triptorelin pamoate 3-month depot; TA 1-mo, triptorelin acetate 1-month depot.
†
GnRH-stimulated LH, FSH peak, and estradiol levels.
‡
LH, FSH, and estradiol levels after administering a GnRHa injection.
§
Basal LH, FSH, and estradiol levels.
∥
TP 3-mo (n=20).